Simmaron is raising funds for studies to scientifically redefine ME/CFS.
Your contributions will expand our ability to execute the strong scientific leads we have.
Columbia Spinal Fluid Studies, Phase 2
Luminex, Proteomic and Metabolomic Discovery in Cerebrospinal Fluid of Patients with CFS/ME, Phase 2: Begun in 2016, this 2-year study is phase 2 of the Columbia spinal fluid studies. Proteomics will be used for biomarker identification and metabolomics to study bacteria and fungi-produced chemicals that enter systemic circulation.
Collaborators: Columbia University, Sierra Internal Medicine, Coppe Healthcare Solutions
Cost: The 2-year cost of this study is $425,000
Data Extraction Studies
Simmaron has unparalleled data from clinical experience monitoring immune testing and utilizing immune-based treatments. We seek funding to extract and statistically analyze clinical experience with treatments, such as Ampligen, cidofovir, and IVIG to publish data that will stimulate more clinical trials in ME/CFS.
Collaborators: Sierra Internal Medicine.
Cost: $100,000 for 2017.
Nested Pathogen Study in Cancer Subset of ME/CFS
This investigation parallels the Columbia spinal fluid studies, focusing on a subset of ME/CFS patients who went on to develop lymphoma or other cancers. The pathogen, proteomics and metabolomics will be performed at The Center for Infection and Immunity at Columbia University’s Mailman School of Public Health.
Collaborators: Columbia University, Sierra Internal Medicine
Donate as we scientifically redefine ME/CFS!
*Simmaron Research supports 10% indirect costs in funded projects.